Cart
sales@molnova.com
ST-168
CAS No. 2126038-25-1
ST-168( ST168 )
Catalog No. M13380 CAS No. 2126038-25-1
ST-168 is a novel potent, orally available MEK/PI3K bifunctional inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameST-168
-
NoteResearch use only, not for human use.
-
Brief DescriptionST-168 is a novel potent, orally available MEK/PI3K bifunctional inhibitor.
-
DescriptionST-168 is a novel potent, orally available MEK/PI3K bifunctional inhibitor with IC50 of 182, 69.2, 1482, 2293, and 41.7 nM for MEK1, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively; exhibits improved inhibition toward PI3K isoforms compared to ST-162; demonstrates superior tumoricidal efficacy over ST-162 in an A375 melanoma spheroid tumor model.
-
In Vitro——
-
In Vivo——
-
SynonymsST168
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2126038-25-1
-
Formula Weight1010.762
-
Molecular FormulaC41H44F5IN10O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN-(2-(2-(2-(3-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-oxopropoxy)ethoxy)ethoxy)ethoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Van Dort ME, et al. ACS Med Chem Lett. 2017 Jul 24;8(8):808-813.
molnova catalog
related products
-
BPR1J-097 hydrochlor...
BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti-tumor activities in vivo.
-
GDC-0941
A potent, selective, orally bioavailable inhibitor of class I PI3Ks with IC50 of 3/33/3/75 nM for p110α/β/γ/δ, respectively.
-
Tenalisib (RP6530)
Tenalisib shows selectivity over PI3K α (>300-fold) and β (>100-fold) isoforms. Tenalisib exhibits modest proliferation inhibition in both HEL-RS and HEL-RR cells.
